文献速递哮喘

严重哮喘的临床评估与分型:一例难治性哮喘的诊治思路

Workup of Severe Asthma.
PubMed 文献 · Chest · 2021-07-13

本文以一例56岁男性难治性哮喘患者为例,系统阐述疑似严重哮喘的临床评估流程,包括确认诊断与治疗依从性、评估合并症及混杂因素、以及通过肺功能与2型炎症生物标志物进行分型。强调激素使用应基于客观炎症证据而非仅凭症状,并指出该患者最终被诊断为ICS抵抗型2型气道炎症的严重哮喘。

要点

  • 严重哮喘评估需先确认诊断和治疗依从性,再排查合并症与混杂因素。
  • 联合肺功能与重复检测血嗜酸性粒细胞计数和呼出气一氧化氮可识别2型炎症驱动或气流阻塞驱动。
  • 激素使用应基于客观炎症证据而非症状,以避免激素相关损害。

核心结论

  • 严重哮喘的评估应确认诊断与依从性、排除合并症,并通过肺功能与2型炎症生物标志物进行分型。
  • 该患者最终诊断为ICS抵抗型2型气道炎症的严重哮喘,需考虑进阶治疗选项。

研究设计与样本

  • 本文为How I Do It系列综述,以一例56岁男性难治性哮喘患者为例阐述临床评估方法。

主要发现

  • 患者有难以控制的哮喘,过去12个月内四次急性加重,尽管使用高剂量吸入性糖皮质激素(ICS)和附加控制治疗。
  • 联合肺功能与重复检测血嗜酸性粒细胞计数和呼出气一氧化氮,可识别疾病控制不佳是由未控制的ICS抵抗型2型气道炎症还是持续气流阻塞驱动。
  • 若缺乏上述任一证据,则提示症状由其他原因驱动,包括慢性气道感染和非哮喘病因。

关键数值与推荐

  • 每种表型代表可治疗特征,需要特定靶向方法。
  • 激素使用应基于客观炎症证据而非仅凭症状。

临床怎么用

  • 对疑似严重哮喘患者,应系统评估诊断、依从性、合并症,并利用肺功能与2型炎症生物标志物进行分型以指导靶向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 56-year-old man has difficult-to-control asthma and a history of four exacerbations in the prior 12 months despite high-dose inhaled corticosteroids (ICS) and additional controller therapies. Is he suitable for more advanced therapeutic options? To address this query, we herein review the clinical assessment of a patient with suspected severe asthma and discuss factors contributing to poor asthma control and how biomarkers assist in disease investigation and stratification. The key components of our multidisciplinary approach are to confirm an asthma diagnosis and adherence to treatment, to assess any contributing comorbidities or confounding factors, and to stratify what type of asthma the patient has. The combination of spirometry and repeated measures of key biomarkers of type 2 airway inflammation-the blood eosinophil count and fractional exhaled nitric oxide-identifies whether poor disease control is driven by uncontrolled, ICS-resistant type 2 airway inflammation or ongoing airflow obstruction. A failure to elicit evidence of either suggests an alternative driver for the patient's symptoms, including chronic airway infection and non-asthma causes. Each phenotype represents a treatable trait that requires a specific targeted approach. Critically, steroids can cause harm, and their use should be guided by objective evidence of inflammation rather than symptoms alone. To conclude, after assessment of treatment adherence and exclusion of relevant comorbidities, the patient was found to have severe asthma with ICS-resistant type 2 airway inflammation. We will consider additional treatment options at our next appointment in part 2/2 of this How I Do It series.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Couillard S, Jackson DJ, Wechsler ME, et al. Workup of Severe Asthma. Chest. 2021. PMID: 34265308. doi:10.1016/j.chest.2021.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。